Human skin-derived fibroblasts acquire in vitro anti-tumor potential after priming with paclitaxel

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 3, 2013, Pages 523-530

  Pessina, Augusto ^a   Coccè, Valentina ^a   Bonomi, Arianna ^a,b,c   Cavicchini, Loredana ^a   Sisto, Francesca ^a   Ferrari, Maura ^d   Ciusani, Emilio ^c,e   Navone, Stefania ^b   Marfia, Giovanni ^b   Parati, Eugenio ^b   Alessandri, Giulio ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b Molecular Neurobiology Laboratory   (Italy)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

^d ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLA LOMBARDIA E DELL EMILIA ROMAGNA   (Italy)

^e Laboratory of Clinical Pathology and Neurogenetic Medicine   (Italy)

Author keywords

Drug uptake; Mesenchymal stem cells; Skin dermal fibroblasts; Stromal cells; Taxol

Indexed keywords

ALPHA4 INTEGRIN; CD31 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; ENDOGLIN; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; PACLITAXEL; THY 1 ANTIGEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG SENSITIVITY; DRUG UPTAKE; FIBROBLAST; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MESENCHYMAL STROMA CELL; OSTEOBLAST; SKIN BIOPSY;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; DELAYED-ACTION PREPARATIONS; FIBROBLASTS; HUMANS; PACLITAXEL; SKIN; TUMOR MICROENVIRONMENT;

EID: 84876719039     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520611313030015     Document Type: Article

References (31)

1. Weldon, J.E.; Xiang, L.; Chertov, O.; Margulies, I.; Kreitman, R.J.; FitzGerald, D.; Pastan, I. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood, 2009, 113(16), 3792-3800.
2. Dhar, S.; Reddy, M.; Shiras, A.; Pokharkar, V.; Prasad, B. Natural Gum Reduced/Stabilized Gold Nanoparticles for Drug Delivery Formulations. Chemistry, 2008, 14(33), 10244-10250.
3. Ciavarella, S.; Dominici, M.; Dammacco, F.; Silvestris, F. Mesenchymal stem cells: a new promise in anticancer therapy. Stem Cells Dev., 2011, 20(1), 1-10.
4. Loebinger, M.R.; Janes, S.M. Stem cells as vectors for antitumour therapy. Thorax, 2010, 65(4), 362-369.
5. Menon, L.G.; Shi, V.J.; Carroll, R.S. Mesenchymal stromal cells as a drug delivery system. StemBook ed. The Stem Cell Res. Commun., 2009, doi/10.3824/stembook.1.35.1.
6. Zhang, J.; Melhem, M.; Kassing, W.; Kellyd, B.; Wanga, Y.; Krishnamoorthye, M.; Heffelfinger, S.; Desai, P.; Roy-Chaudhury, P. In vitro paclitaxel and radiation effects on the cell types responsible for vascular stenosis: a preliminary analysis. Blood Purif., 2007, 25(2), 155-160.
7. Pessina, A.; Piccirillo, M.; Mineo, E.; Catalani, P.; Gribaldo, L.; Marafante, E.; Neri, M.G.; Raimondi, A. Role of SR-4987 stromal cells in the modulation of doxorubicin toxicity to in vitro granulocyte-macrophage progenitors (CFU-GM). Life Sci., 1999, 65(5), 513-523.
8. Pessina, A.; Bonomi, A.; Coccè, V.; Invernici, G.; Navone, S.; Cavicchini, L.; Sisto, F.; Ferrari, M.; Viganò, L.; Locatelli, A.; Ciusani, E.; Cappelletti, G.; Cartelli, D.; Arnaldo, C.; Parati, E.; Marfia, G.; Pallini, R.; Falchetti, M.L.; Alessandri, G. Mesenchimal stromal cells primed with paclitaxel provide a new approach for cancer therapy. PloS ONE, 2011, 6 (12), e28321.
9. Blasi, A.; Martino, C.; Balducci, L.; Saldarelli, M.; Soleti, A.; Navone, S.E.; Canzi, L.; Cristini, S.; G Invernici, G.; Parati, E.A.; and Alessandri, G. Dermal fibroblasts display similar phenotypic and differentiation capacity to fat-derived mesenchymal stem cells, but differ in anti-inflammatory and angiogenic potential. Vasc. Cell., 2011, 3, 5.
10. Wagner, W.; Wein, F.; Seckinger, A. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp. Hematol., 2005; 33, 1402-1416.
11. Lorenz, K.; Sicker, M.; Schmelzer, E.; Rupf, T.; Salvetter, J.; Schulz-Siegmund, M.; Bader, A. Multilineage differentiation potential of human dermal skin-derived fibroblasts. Exp. Dermatol., 2008, 17, 925-932.
12. Roni, V.; Habeler, W.; Parenti, A.; Indraccolo, S.; Gola, E.; Tosello, V.; Cortivo, R.; Abatangelo, G.; Chieco-Bianchi, L.; Amadori, A. Recruitment of human umbilical vein endothelial cells and human primary fibroblasts into experimental tumors growing in SCID mice. Exp. Cell Res., 2003, 287(1):28-38.
13. Minowada, J.; Ohmuma, M.D.; Moore, G.E. Rosette forming human lymphoid cell lines. Establishment and evidence of origin of thymus-derived lymphocytes. J. Natl. Cancer Inst., 1972, 49, 891-895.
14. Pessina, A.; Eletti, B.; Croera, C.; Savalli, N.; Diodovich, C.; Gribaldo, L. Pancreas developing markers expressed on human mononucleated umbilical cord blood cells. Biochem. Biophys. Res. Commun., 2004, 323, 315-322.
15. Pittenger, M.F.; Mackay, A.M.; Beck, S.C.; Jaiswal, R.K.; Douglas, R.; Mosca, J.D.; Moorman, M.A.; Simonetti, D.W.; Craig, S.; Marshak, D.R. Multilineage potential of adult human mesenchymal stem cells. Science, 1999, 284, 143-147.
16. Wrasidlo, W.; Gaedicke, G.; Guy, R.K.; Renaud, J.; Pitsinos, E.; Nicolaou, K.C.; Reisfeld, R.A.; Lode, H.N. A novel 2'-(N-methylpyridinium acetate) prodrug of paclitaxel induces superior antitumor responses in preclinical cancer models. Bioconjug. Chem., 2002, 13, 1093-1099.
17. Reed, L.J.; Muench, H. A simple method of estimating fifty percent endpoints. Am. J. Hygiene, 1938, 27, 493-497.
18. Koch, C.M.; Suschek, C.V.; Lin, Q.; Bork, S.; Goergens, M.; Joussen, S.; Pallua, N.; Ho, A.D.; Zenke, M.; Wagner, W. Specific age-associated DNA methylation changes in human dermal fibroblasts. PloS ONE, 2011, 6(2), e16679.
19. Kiseleva, E.V.; Chermnykh, E.S.; Voroteliak, E.A.; Volozhin, A.I.; Vasil'ev, A.V.; Terskikh, V.V. Differentiation capacity of stromal fibroblast-like cells from human bone marrow, adipose tissue, hair follicle dermal papilla and derma. Cell and Tissue Biol., 2009, 3, 42-49.
20. Schiff, P.B.; Fant, J.; Horwitz, S.B. Promotion of microtubule assembly in vitro by taxol. Nature, 1979, 277(5698), 665-7.
21. Belotti, D.; Vergani, V.; Drudis, T.; Borsotti, P.; Pitelli, M. R; Viale, G.; Giavazzi, R.; Taraboletti, G. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res., 1996, 2(11), 1843-1849.
22. Strunk, D.; Rohde, E.; Lanzer, G.; Linkesch, W. Phenotypic characterization and preclinical production of human lineage-negative cells for regenerative stem cell therapy. Transfusion, 2005, 45(3), 315-26.
23. Heneberg, P. Mast Cells and Basophils: Trojan Horses of Conventional Lin- Stem/Progenitor Cells Isolates. Curr. Pharm. Des., 2011, 17(34), 3753-71.
24. Gille, L.; Nohl, H. Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. Free Radic. Biol. Med., 1997, 23(5), 775-782.
25. Singla, A.K.; Garg, A.; Aggarwal, D. Paclitaxel and its formulations. Int. J. Pharm., 2002, 235(1-2), 179-92.
26. Kane, S.E.; Pastan, I.; Gottesman, M.M. Genetic basis of multidrug resistance of tumor cells. J. Bioenerg. Biomembr., 1990, 22(4), 593-618.
27. Chaudhary, P.M.; Roninson, I.B. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J. Natl. Cancer Ins., 1993, 85(8), 632-639.
28. Hansbrough, J.F.; Cooper, M.L.; Cohen, R.; Spielvogel, R.; Greenleaf, G.; Bartel, R.L.; Naughton, G. Evaluation of a biodegradable matrix containing cultured human fibroblasts as a dermal replacement beneath meshed skin grafts on athymic mice. Surgery, 1992, 111(4), 438-446.
29. Cooper, M.L.; Hansbrough, J.F.; Spielvogel, R.L.; Cohen, R.; Bartel, R.L.; Naughton, G. "In vivo" optimization of a living dermal substitute employing cultured human fibroblasts on a biodegradable polyglycolic acid or polyglactin mesh. Biomaterials, 1991, 12(2), 243-248.
30. Dominici, M.; Le Blanc, K.; Mueller, I.; Slaper-Cortenbach, I.; Marini, F.; Krause, D.; Deans, R.; Keating, A.; Prockop, DJ.; Horwitz, E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 2006, 8(4), 315-317.
31. Chen, F.G.; Zhang, W.J.; Bi, D.; Liu, W.; Wei, X.; Chen, F.F.; Zhu, L.; Cui, L.; Cao, Y. Clonal analysis of nestin(-) vimentin(+) multipotent fibroblasts isolated from human dermis. J. Cell. Sci., 2007, 120(16), 2875-83.